↓ Skip to main content

ALK-positive anaplastic large cell lymphoma limited to the skin: clinical, histopathological and molecular analysis of 6 pediatric cases. A report from the ALCL99 study

Overview of attention for article published in Hematology Journal, July 2012
Altmetric Badge

Mentioned by

f1000
1 research highlight platform

Citations

dimensions_citation
108 Dimensions

Readers on

mendeley
41 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
ALK-positive anaplastic large cell lymphoma limited to the skin: clinical, histopathological and molecular analysis of 6 pediatric cases. A report from the ALCL99 study
Published in
Hematology Journal, July 2012
DOI 10.3324/haematol.2012.065664
Pubmed ID
Authors

Ilske Oschlies, Jasmin Lisfeld, Laurence Lamant, Atsuko Nakazawa, Emanuele S. G. d'Amore, Ulrika Hansson, Konnie Hebeda, Ingrid Simonitsch-Klupp, Jadwiga Maldyk, Leonhard Müllauer, Marianne Tinguely, Markus Stücker, Marie-Cecile LeDeley, Reiner Siebert, Alfred Reiter, Laurence Brugières, Wolfram Klapper, Wilhelm Woessmann

Abstract

Anaplastic large cell lymphomas are peripheral T-cell lymphomas that are characterized by a proliferation of large anaplastic blasts expressing CD30. In children, systemic anaplastic large cell lymphomas often present at advanced clinical stage and harbor translocations involving the anaplastic lymphoma kinase (ALK) gene leading to the expression of chimeric anaplastic lymphoma kinase (ALK)-fusion proteins. Primary cutaneous anaplastic large cell lymphoma is regarded as an ALK-negative variant confined to the skin and is part of the spectrum of primary cutaneous CD30-positive T-cell lymphoproliferative disorders. Thirty-three of 487 pediatric patients registered within the Anaplastic Large Cell Lymphoma-99 trial (1999 to 2006) presented with a skin limited CD30-positive lympho-proliferative disorder. In 23 of the 33 patients, material for international histopathological review was available, and the cases were studied for histopathological, immunophenotypical and clinical features as well as for breaks within the ALK gene. Five of 23 cases and one additional case (identified after closure of the trial) expressed ALK-protein. Complete staging excluded any other organ involvement in all children. Expression of ALK proteins was demonstrated by immunohistochemistry in all cases and the presence of breaks of the ALK gene was genetically confirmed in 5 evaluable cases. The histopathological and clinical picture of these skin-restricted ALK-positive lymphomas was indistinguishable from that of cutaneous anaplastic large cell lymphoma. Five children presented with a single skin lesion that was completely resected in 4 and incompletely resected in one. Three of these patients received no further therapy, 2 additional local radiotherapy, and one chemotherapy. All children remain in complete remission with a median follow up of seven years (range 1-8 years). We present 6 pediatric cases of ALK-positive primary cutaneous anaplastic large cell lymphomas. After thorough exclusion of systemic involvement, therapy confined to local measures seems to be sufficient to induce cure.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 41 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 7 17%
Other 6 15%
Student > Ph. D. Student 5 12%
Student > Doctoral Student 4 10%
Student > Postgraduate 4 10%
Other 10 24%
Unknown 5 12%
Readers by discipline Count As %
Medicine and Dentistry 24 59%
Agricultural and Biological Sciences 3 7%
Immunology and Microbiology 2 5%
Biochemistry, Genetics and Molecular Biology 2 5%
Pharmacology, Toxicology and Pharmaceutical Science 1 2%
Other 2 5%
Unknown 7 17%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 September 2012.
All research outputs
#17,285,036
of 25,373,627 outputs
Outputs from Hematology Journal
#2,984
of 4,083 outputs
Outputs of similar age
#117,183
of 177,697 outputs
Outputs of similar age from Hematology Journal
#37
of 42 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,083 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.4. This one is in the 18th percentile – i.e., 18% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 177,697 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 24th percentile – i.e., 24% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 42 others from the same source and published within six weeks on either side of this one. This one is in the 7th percentile – i.e., 7% of its contemporaries scored the same or lower than it.